Oncolytic Virus Therapies Market Size, Share & Growth Analysis By Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), By Application (Solid Tumors, Melanoma), By End-Use (Hospitals, Specialty Clinics, Cancer Research Institute), And Regional Forecast, 2021-2027

Report Summary

The Global Oncolytic Virus Therapies Market Size, Share & Growth Analysis By Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), By Application (Solid Tumors, Melanoma), By End-Use (Hospitals, Specialty Clinics, Cancer Research Institute), And Regional Forecast, 2021-2027, This research & consulting report doles out information about the global Oncolytic Virus Therapies market. The forecast period of the market extends till 2027, while commencing in 2020. The report sheds light on various key insights & trends that have occupied center stage & drawn the attention of end-users. The Oncolytic Virus Therapies industry is witnessing impressive expansion at present, having logged double digit CAGRs in the past.

The global oncolytic virus therapies market size is expected to reach $619.7 Million in 2027 and register a compound annual growth rate (CAGR) of 26.1% during the forecast period.

The report alludes to the Oncolytic Virus Therapies market as a lucrative sector. This sector is slated to generate substantial revenues during forecast period 2021 to 2027. The analytical report highlights data & overview regarding the size, shares, & demand of Oncolytic Virus Therapies. Several other factors have had a positive or negative impact on the industry, all of which have been laid out in details.

To know more about this report: request pdf sample copy

Pros & Scope of The Report

The said factors comprise drivers, novel prospects, hindrances, and other vital characteristics of the market. Investments by rivals into Oncolytic Virus Therapies products have catapulted the market into limelight & have stoked its demand, globally.

Few among other key aspects that find a mention; encompass the industry segments, predictions, & size and shares for 2021 to 2027. Besides these; the report narrows down on the innovative trends & technological developments, expansion strategies of key players, and regional statistics.

Some Of The Companies For Oncolytic Virus Therapies Market Are:

• Oncolytics Biotech, Inc.
• Amgen Inc.
• Sorrento Therapeutics, Inc.
• Transgene SA
• Daiichi Sankyo Company, Limited
• Shanghai Sunway Biotech Co., Ltd.
• Takara Bio Inc.
• PsiOxus Therapeutics
• SillaJen, Inc.
• ViroCure

More Inputs & Objectives

The manner in which nascent & local competitors stack up against prominent players, hogs the spotlight. Novel products & services, coupled with the monetary shares of eminent competitors and the SWOT analysis unveil the complexities of the global industry size.

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends from 2021 to 2027 in each of the sub segments. For the purpose of this study, Eternity Insights has segmented the global Oncolytic Virus Therapies market on the basis of virus type, application, end-use and region:

Oncolytic Virus Therapies Market, By Virus Type

• Genetically Engineered Oncolytic Viruses
  • Herpes Simplex Virus
  • Adenovirus
  • Vaccinia Virus
• Oncolytic Wild-Type Viruses
  • Reovirus
  • Newcastle Disease Virus
  • Vesicular Stomatitis Virus

Oncolytic Virus Therapies Market, By Application

• Solid Tumors
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Glioblastoma
• Melanoma
  • Hematological Malignancies
  • Lymphoma
  • Leukemia
  • Myeloma

Oncolytic Virus Therapies Market, By End-use

• Hospitals
• Specialty Clinics
• Cancer Research Institute

Oncolytic Virus Therapies Market, By Regional Outlook

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • BENELUX
  • Italy
  • Spain
  • Switzerland
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Rest of APAC
• Latin America
  • Brazil
  • Rest of LATAM
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Turkey
  • Rest of MEA

To know more about this report: request pdf sample copy

Research Methodology

Research methodology is an integral component of any kind of high-level market research. It entails evaluation by expert panels, research on secondary & primary levels, checks on quality, & testing on completion. Secondary research deeply focuses on the whys, whos, wheres, whens, & hows and caters to answering the strictly consumer-centric base of people.

Some other secondary research sources comprise governmental affiliations & blogs, business magazines, and industrial journals. Primary research includes face-to-face & telephonic interviews with industry experts. It is comparatively more detailed & lays stress on unprejudiced opinions about the products & services.

Primary research findings cement secondary research & help end-users & businesses get a better hang of various markets. It is a well-established fact, though, that research methodology is best implemented through the mixed execution of its aforementioned procedures.

What Does the Report Offer?

• A break down & profiling of the qualitative & quantitative analysis of the industry.
• An in-depth overview of the segments & sub-segments of the industry, unlocking their shares and positions.
• Data on market players & their growth strategies.
• Industry outlook, via value chains.
• Mergers & acquisitions, the SWOT analysis of prominent competitors, and high-tech product launches.
• Drivers, hindrances, factors that positively & negatively impact the market, and new opportunities.
• Crucial information and actionable insights, enabling businesses to widen their traction & to have an edge over others.
• Regions into which the global market is fragmented and the reigning regional markets & their respective shares & revenues.
• Analytical support on the purchases made/orders passed.

Other Vital Points That Are Covered

The impact of Covid-19 on each of the segments of the Oncolytic Virus Therapies market.

The suppliers, manufacturers, raw materials, dominating players, etc.

Key regional contributors & their shares in the past and the future.

Evaluation of most of the important countries within particular regions in view of their revenues, supplies, supremacy, business returns, & consumption volumes.

Advanced technologies that surround the market and comprehensive outlook on industry applications, products, end-users, & regions.

Technological & statistical data to cater to the demands of businesses, shareholders, & companies and to help them grow further.

Comparison of competitors against other players and the dominant companies during the forecast period. Strategies employed by reigning stakeholders to gain further traction & to generate higher revenues.

End users that are ahead in the rat race and the positive factors that influence those end users.

Applications that should come out on top by the end of the forecast period.

Products that occupy the maximum shares and the drivers behind those products.

Factors that bode well for the Oncolytic Virus Therapies market and a mention of other industries that are closely associated with the Oncolytic Virus Therapies market.

Regions that open the floodgates to higher investments and greater opportunities.

Records of the market sales, volumes, CAGRs, & shares.

The market report also brings to light major opportunities and untapped geographies. It is more like a blend of customized research documents & conventional reports. Besides informing buyers about the pros & cons of direct and indirect sales channels, the analysis exhibits illustrations & graphical representations of industry growth and the innovative trends within the industry.

 

Table Of Contents

Table of Content

Chapter 1. Methodology & Sources

    1.1. Market Definition

    1.2. Research Scope 

    1.3. Methodology

    1.4. Research Sources

          1.4.1. Primary

          1.4.2. Secondary

          1.4.3. Paid Sources

    1.5. Market Estimation Technique

Chapter 2. Executive Summary

    2.1. Summary Snapshot, 2020-2027

Chapter 3. Key Insights

Chapter 4. Oncolytic Virus Therapies Market Segmentation & Impact Analysis

    4.1. Oncolytic Virus Therapies Market Material Segmentation Analysis

    4.2. Industrial Outlook

          4.2.1. Market indicators analysis

          4.2.2. Market drivers analysis

                    4.2.2.1. Rising number of clinical trials

                    4.2.2.2. Increasing adoption of inorganic growth strategies in the market

          4.2.3. Market restraints analysis

                    4.2.3.1. High cost of therapy

    4.3. Technological Insights

    4.4. Regulatory Framework

    4.5. Porter’s Five Forces Analysis

    4.6. Competitive Metric Space Analysis

    4.7. Price trend Analysis

    4.8. Covid-19 Impact Analysis

Chapter 5. Oncolytic Virus Therapies Market By Virus Type Insights & Trends, Revenue (USD Million)

    5.1. Virus Type Dynamics & Market Share, 2021 & 2027

          5.1.1. Genetically Engineered Oncolytic Viruses

                    5.1.1.1. Herpes Simplex Virus

                    5.1.1.2. Adenovirus

                    5.1.1.3. Vaccinia Virus

          5.1.2. Oncolytic Wild-Type Viruses

                    5.1.2.1. Reovirus

                    5.1.2.2. Newcastle Disease Virus

                    5.1.2.3. Vesicular Stomatitis Virus

Chapter 6. Oncolytic Virus Therapies Market By Application Insights & Trends Revenue (USD Million)

    6.1. Application Dynamics & Market Share, 2021 & 2027

          6.1.1. Solid Tumors

                    6.1.1.1. Breast Cancer

                    6.1.1.2. Prostate Cancer

                    6.1.1.3. Lung Cancer

                    6.1.1.4. Glioblastoma

                    6.1.1.5. Melanoma

          6.1.2. Hematological Malignancies

                    6.1.2.1. Lymphoma

                    6.1.2.2. Leukemia

                    6.1.2.3. Myeloma

Chapter 7. Oncolytic Virus Therapies Market By End-use Insights & Trends Revenue (USD Million)

    7.1. End-use Dynamics & Market Share, 2021 & 2027

          7.1.1. Hospitals

          7.1.2. Specialty Clinics

          7.1.3. Cancer Research Institute

Chapter 8. Oncolytic Virus Therapies Market Regional Outlook

    8.1. Oncolytic Virus Therapies Market Share By Region, 2021 & 2027

    8.2. North America

          8.2.1. Market By Virus Type, Market Estimates and Forecast, USD Billion

                    8.2.1.1. Genetically Engineered Oncolytic Viruses

                                8.2.1.1.1. Herpes Simplex Virus

                                8.2.1.1.2. Adenovirus

                                8.2.1.1.3. Vaccinia Virus

                    8.2.1.2. Oncolytic Wild-Type Viruses

                                8.2.1.2.1. Reovirus

                                8.2.1.2.2. Newcastle Disease Virus

                                8.2.1.2.3. Vesicular Stomatitis Virus

          8.2.2. Market By Application, Market Estimates and Forecast, USD Billion

                    8.2.2.1. Solid Tumors

                                8.2.2.1.1. Breast Cancer

                                8.2.2.1.2. Prostate Cancer

                                8.2.2.1.3. Lung Cancer

                                8.2.2.1.4. Glioblastoma

                    8.2.2.2. Melanoma

                                8.2.2.2.1. Hematological Malignancies

                                8.2.2.2.2. Lymphoma

                                8.2.2.2.3. Leukemia

                                8.2.2.2.4. Myeloma

          8.2.3. Market By End-use, Market Estimates and Forecast, USD Billion

                    8.2.3.1. Hospitals

                    8.2.3.2. Specialty Clinics

                    8.2.3.3. Cancer Research Institute

          8.2.4. Market By Country, Market Estimates and Forecast, USD Billion

                    8.2.4.1. US

                    8.2.4.2. Canada

                    8.2.4.3. Mexico

    8.3. Europe

          8.3.1. Market By Virus Type, Market Estimates and Forecast, USD Billion

                    8.3.1.1. Genetically Engineered Oncolytic Viruses

                                8.3.1.1.1. Herpes Simplex Virus

                                8.3.1.1.2. Adenovirus

                                8.3.1.1.3. Vaccinia Virus

                    8.3.1.2. Oncolytic Wild-Type Viruses

                                8.3.1.2.1. Reovirus

                                8.3.1.2.2. Newcastle Disease Virus

                                8.3.1.2.3. Vesicular Stomatitis Virus

          8.3.2. Market By Application, Market Estimates and Forecast, USD Billion

                    8.3.2.1. Solid Tumors

                                8.3.2.1.1. Breast Cancer

                                8.3.2.1.2. Prostate Cancer

                                8.3.2.1.3. Lung Cancer

                                8.3.2.1.4. Glioblastoma

                    8.3.2.2. Melanoma

                                8.3.2.2.1. Hematological Malignancies

                                8.3.2.2.2. Lymphoma

                                8.3.2.2.3. Leukemia

                                8.3.2.2.4. Myeloma

          8.3.3. Market By End-use, Market Estimates and Forecast, USD Billion

                    8.3.3.1. Hospitals

                    8.3.3.2. Specialty Clinics

                    8.3.3.3. Cancer Research Institute

          8.3.4. Market By Country, Market Estimates and Forecast, USD Billion

                    8.3.4.1. Germany

                    8.3.4.2. U.K.

                    8.3.4.3. France

                    8.3.4.4. Spain

                    8.3.4.5. BENELUX

                    8.3.4.6. Rest of Europe

    8.4. Asia-Pacific

          8.4.1. Market By Virus Type, Market Estimates and Forecast, USD Billion

                    8.4.1.1. Genetically Engineered Oncolytic Viruses

                                8.4.1.1.1. Herpes Simplex Virus

                                8.4.1.1.2. Adenovirus

                                8.4.1.1.3. Vaccinia Virus

                    8.4.1.2. Oncolytic Wild-Type Viruses

                                8.4.1.2.1. Reovirus

                                8.4.1.2.2. Newcastle Disease Virus

                                8.4.1.2.3. Vesicular Stomatitis Virus

          8.4.2. Market By Application, Market Estimates and Forecast, USD Billion

                    8.4.2.1. Solid Tumors

                                8.4.2.1.1. Breast Cancer

                                8.4.2.1.2. Prostate Cancer

                                8.4.2.1.3. Lung Cancer

                                8.4.2.1.4. Glioblastoma

                    8.4.2.2. Melanoma

                                8.4.2.2.1. Hematological Malignancies

                                8.4.2.2.2. Lymphoma

                                8.4.2.2.3. Leukemia

                                8.4.2.2.4. Myeloma

          8.4.3. Market By End-use, Market Estimates and Forecast, USD Billion

                    8.4.3.1. Hospitals

                    8.4.3.2. Specialty Clinics

                    8.4.3.3. Cancer Research Institute

          8.4.4. Market By Country, Market Estimates and Forecast, USD Billion

                    8.4.4.1. China

                    8.4.4.2. India

                    8.4.4.3. Japan

                    8.4.4.4. South Korea

                    8.4.4.5. Rest of APAC

    8.5. Latin America

          8.5.1. Market By Virus Type, Market Estimates and Forecast, USD Billion

                    8.5.1.1. Genetically Engineered Oncolytic Viruses

                                8.5.1.1.1. Herpes Simplex Virus

                                8.5.1.1.2. Adenovirus

                                8.5.1.1.3. Vaccinia Virus

                    8.5.1.2. Oncolytic Wild-Type Viruses

                                8.5.1.2.1. Reovirus

                                8.5.1.2.2. Newcastle Disease Virus

                                8.5.1.2.3. Vesicular Stomatitis Virus

          8.5.2. Market By Application, Market Estimates and Forecast, USD Billion

                    8.5.2.1. Solid Tumors

                                8.5.2.1.1. Breast Cancer

                                8.5.2.1.2. Prostate Cancer

                                8.5.2.1.3. Lung Cancer

                                8.5.2.1.4. Glioblastoma

                    8.5.2.2. Melanoma

                                8.5.2.2.1. Hematological Malignancies

                                8.5.2.2.2. Lymphoma

                                8.5.2.2.3. Leukemia

                                8.5.2.2.4. Myeloma

          8.5.3. Market By End-use, Market Estimates and Forecast, USD Billion

                    8.5.3.1. Hospitals

                    8.5.3.2. Specialty Clinics

                    8.5.3.3. Cancer Research Institute

          8.5.4. Market By Country, Market Estimates and Forecast, USD Billion

                    8.5.4.1. Brazil

                    8.5.4.2. Rest of LATAM

    8.6. Middle East and Africa

          8.6.1. Market By Virus Type, Market Estimates and Forecast, USD Billion

                    8.6.1.1. Genetically Engineered Oncolytic Viruses

                                8.6.1.1.1. Herpes Simplex Virus

                                8.6.1.1.2. Adenovirus

                                8.6.1.1.3. Vaccinia Virus

                    8.6.1.2. Oncolytic Wild-Type Viruses

                                8.6.1.2.1. Reovirus

                                8.6.1.2.2. Newcastle Disease Virus

                                8.6.1.2.3. Vesicular Stomatitis Virus

          8.6.2. Market By Application, Market Estimates and Forecast, USD Billion

                    8.6.2.1. Solid Tumors

                                8.6.2.1.1. Breast Cancer

                                8.6.2.1.2. Prostate Cancer

                                8.6.2.1.3. Lung Cancer

                                8.6.2.1.4. Glioblastoma

                    8.6.2.2. Melanoma

                                8.6.2.2.1. Hematological Malignancies

                                8.6.2.2.2. Lymphoma

                                8.6.2.2.3. Leukemia

                                8.6.2.2.4. Myeloma

          8.6.3. Market By End-use, Market Estimates and Forecast, USD Billion

                    8.6.3.1. Hospitals

                    8.6.3.2. Specialty Clinics

                    8.6.3.3. Cancer Research Institute

          8.6.4. Market By Country, Market Estimates and Forecast, USD Billion

                    8.6.4.1. Saudi Arabia

                    8.6.4.2. UAE

                    8.6.4.3. Israel

                    8.6.4.4. Rest of MEA

Chapter 9. Competitive Landscape

    9.1. Market Revenue Share By Manufacturers

    9.2. Mergers & Acquisitions

    9.3. Competitor’s Positioning

    9.4. Strategy Benchmarking

    9.5. Vendor Landscape

          9.5.1. Raw Material Suppliers

                    9.5.1.1. North America

                    9.5.1.2. Europe

                    9.5.1.3. Asia Pacific

                    9.5.1.4. Middle East & Africa

                    9.5.1.5. Latin America

          9.5.2. Distributors

                    9.5.2.1. North America

                    9.5.2.2. Europe

                    9.5.2.3. Asia Pacific

                    9.5.2.4. Middle East & Africa

                    9.5.2.5. Latin America

          9.5.3. Others

Chapter 10. Company Profiles

    10.1. Oncolytics Biotech, Inc.

          10.1.1. Company Overview

          10.1.2. Product & Service Offerings

          10.1.3. Strategic Initiatives

          10.1.4. Financials

          10.1.5. Eternity Insights

    10.2. Amgen Inc.

          10.2.1. Company Overview

          10.2.2. Product & Service Offerings

          10.2.3. Strategic Initiatives

          10.2.4. Financials

          10.2.5. Eternity Insights

    10.3. Sorrento Therapeutics, Inc.

          10.3.1. Company Overview

          10.3.2. Product & Service Offerings

          10.3.3. Strategic Initiatives

          10.3.4. Financials

          10.3.5. Eternity Insights

    10.4. Transgene SA

          10.4.1. Company Overview

          10.4.2. Product & Service Offerings

          10.4.3. Strategic Initiatives

          10.4.4. Financials

          10.4.5. Eternity Insights

    10.5. Daiichi Sankyo Company, Limited

          10.5.1. Company Overview

          10.5.2. Product & Service Offerings

          10.5.3. Strategic Initiatives

          10.5.4. Financials

          10.5.5. Eternity Insights

    10.6. Shanghai Sunway Biotech Co., Ltd.

          10.6.1. Company Overview

          10.6.2. Product & Service Offerings

          10.6.3. Strategic Initiatives

          10.6.4. Financials

          10.6.5. Eternity Insights

    10.7. Takara Bio Inc.

          10.7.1. Company Overview

          10.7.2. Product & Service Offerings

          10.7.3. Strategic Initiatives

          10.7.4. Financials

          10.7.5. Eternity Insights

    10.8. PsiOxus Therapeutics

          10.8.1. Company Overview

          10.8.2. Product & Service Offerings

          10.8.3. Strategic Initiatives

          10.8.4. Financials

          10.8.5. Eternity Insights

    10.9. SillaJen, Inc.

          10.9.1. Company Overview

          10.9.2. Product & Service Offerings

          10.9.3. Strategic Initiatives

          10.9.4. Financials

          10.9.5. Eternity Insights

    10.10. ViroCure

          10.10.1. Company Overview

          10.10.2. Product & Service Offerings

          10.10.3. Strategic Initiatives

          10.10.4. Financials

          10.10.5. Eternity Insights